Adalimumab for moderate to severe chronic plaque psoriasis
Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
Papp K, Crowley J, Ortonne JP, Leu J, Okun M, Gupta SR, Gu Y, Langley RG.
Probity Medical Research, Waterloo, Ontario, Canada Bakersfield Dermatology, Bakersfield, California, United States Nice University Hospital, Nice, France Abbott Laboratories, Abbott Park, Illinois, United States Dalhousie University, Halifax, Nova Scotia.